# Rituximab in IgG4-RD: A Phase 1-2 Trial

> **NCT01584388** · PHASE1,PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 30 (actual)

## Conditions studied

- Retroperitoneal Fibrosis
- Autoimmune Pancreatitis
- Sialadenitis
- Pseudotumor

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01584388
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-01
- **Final completion:** 2015-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01584388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01584388, "Rituximab in IgG4-RD: A Phase 1-2 Trial". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01584388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*